1.https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-advanced-esophageal-squamous-cell-cancer 2.https://www.onclive.com/web-exclusives/fda-approves-nivolumab-for-esophageal-cancer 3.https://www.drugs.com/newdrugs/fda-approves-opdivo-nivolumab-patients-advanced-es...
结果显示, 纳武利尤单抗单药ORR为11%,O+伊匹联用ORR为23%,双免疫的疗效翻倍。按PDL1表达分层,未能看出疗效的差异。同样,双免疫治疗的中位OS也优于纳武利尤单抗单药,为7.8 vs 4.1个月。 (仅供医药专业人士参考) CN-55436 参考...
Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and antiangiogenic drugs for hepatocellular carcinoma: a systematic review and meta-analysisXIAN, F.WU, J.YUAN, Y.-L.BIE, J.XU, G.-H.European Review for Medical & Pharmacological Sciences...
Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. J. Clin. Oncol. 33 (Suppl.), 8029 (2015). Article Google Scholar Spira, A. I. et al. Efficacy, safety and ...
(C) Effect of YIV-906 and/or Anti-PD1 on mRNA expression related to T cell of Hepa 1–6 tumor. Using qRT-PCR. T-test P values were shown in the graph. The PD1 (D) and PDL1 (E) protein expression of Hepa 1–6 tumor following YIV-906 and/or Anti-PD1 treatment. Western blot ...
The direct anti-tumor function of HCQ and the upregulation of surface MHC-I, PDL1, and PDL2 suggest the potential anti-tumor benefits of HCQ treatment when combined with anti-PD1 therapy. HCQ treatment impairs anti-PD1 response in tumor-bearing mice The counteracting effects of HCQ between ...